SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice

Published: 27 August 2021

  • Views:

    Views Icon 6408
  • Likes:

    Heart Icon 4

Overview

Full programme

  • Views:

    Views Icon 6408
  • Likes:

    Heart Icon 4

Overview

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Andrew Coats (Monash University, Australia and University of Warwick, UK) and Prof Giuseppe Rosano (St George's, University of London, UK) discuss the implications for treatment strategies.

 

This three-part series provides comprehensive update on some of the most important developments in HFrEF management including addressing key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF, when and how to initiate SGLT-2 inhibitors, and making evidence-based choices in the selection of SGLT-2 inhibitor.

This programme is supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Recall the latest recommendations and levels of evidence supporting the use of SGLT-2 inhibitors in heart failure (HF)
  • Consider the impact of delaying the adoption of all guideline-directed foundational therapies in existing HF
  • Make an evidence-based choice when selecting an SGLT-2 inhibitor in HF

Target Audience

  • Heart failure specialists
  • Cardiologists
  • Referring physicians
  • Allied health professionals

Series overview

Part 1

Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?

1 session

  • Where Do SGLT-2 Inhibitors Fit Into the New Guidelines?

    Watch now

Part 2

When and How to Initiate SGLT-2 Inhibitors in HFrEF

1 session

  • When and How to Initiate SGLT-2 Inhibitors in HFrEF

    Watch now

Part 3

Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice

1 session

  • Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice

    Watch now

Faculty biographies